FoxP3+, and not CD25+, T cells increase post-transplant in islet allotransplant recipients following anti-CD25+ rATG immunotherapy

Kelly Hire, Diem K. Ngo, Kristen M. Stewart-Maynard, Bernhard Hering, Pratima Bansal-Pakala

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Anti-CD25 antibodies are used as an induction therapy in islet allotransplantation for type 1 diabetes. Although previous reports suggested that anti-CD25 treatment may lead to depletion of CD4+CD25+ regulatory T cells (Tregs) and questioned its use in tolerance-promoting protocols for transplantation, the effect of anti-CD25 antibodies on the frequency and function of Tregs remains unclear. We examined the effect of anti-CD25 antibody, daclizumab, in vivo on Tregs in islet allograft recipients enrolled in a single-center study and monitored post-transplant. Our data shows that the reduction in CD25+ Treg cells observed post-transplant is due to masking of CD25 receptor by daclizumab and not due to depletion. In addition, using Treg marker, FoxP3, we show that anti-CD25+ ATG treatment leads to an increase in FoxP3+ Tregs post-transplant. These data suggest that anti-CD25-based therapy has beneficial effects on Tregs and combined with ATG may be a promising therapy for autoimmunity and transplantation.

Original languageEnglish (US)
Pages (from-to)83-88
Number of pages6
JournalCellular Immunology
Volume274
Issue number1-2
DOIs
StatePublished - Feb 22 2012

Keywords

  • Anti-CD25
  • Daclizumab
  • FoxP3
  • Islet transplantation
  • Regulatory T cells
  • Tregs

Fingerprint Dive into the research topics of 'FoxP3+, and not CD25+, T cells increase post-transplant in islet allotransplant recipients following anti-CD25+ rATG immunotherapy'. Together they form a unique fingerprint.

  • Cite this